Current Atherosclerosis Reports最新文献_第9页

What Causes Premature Coronary Artery Disease? 什么原因导致冠心病早发？

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2024-04-04 DOI: 10.1007/s11883-024-01200-y

Ann Le, Helen Peng, Danielle Golinsky, Matteo Di Scipio, Ricky Lali, Guillaume Paré

{"title":"What Causes Premature Coronary Artery Disease?","authors":"Ann Le, Helen Peng, Danielle Golinsky, Matteo Di Scipio, Ricky Lali, Guillaume Paré","doi":"10.1007/s11883-024-01200-y","DOIUrl":"https://doi.org/10.1007/s11883-024-01200-y","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3>This review provides an overview of genetic and non-genetic causes of premature coronary artery disease (pCAD).<h3 data-test=\"abstract-sub-heading\">Recent Findings</h3>pCAD refers to coronary artery disease (CAD) occurring before the age of 65 years in women and 55 years in men. Both genetic and non-genetic risk factors may contribute to the onset of pCAD. Recent advances in the genetic epidemiology of pCAD have revealed the importance of both monogenic and polygenic contributions to pCAD. Familial hypercholesterolemia (FH) is the most common monogenic disorder associated with atherosclerotic pCAD. However, clinical overreliance on monogenic genes can result in overlooked genetic causes of pCAD, especially polygenic contributions. Non-genetic factors, notably smoking and drug use, are also important contributors to pCAD. Cigarette smoking has been observed in 25.5% of pCAD patients relative to 12.2% of non-pCAD patients. Finally, myocardial infarction (MI) associated with spontaneous coronary artery dissection (SCAD) may result in similar clinical presentations as atherosclerotic pCAD.<h3 data-test=\"abstract-sub-heading\">Summary</h3>Recognizing the genetic and non-genetic causes underlying pCAD is important for appropriate prevention and treatment. Despite recent progress, pCAD remains incompletely understood, highlighting the need for both awareness and research.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"117 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140583094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment. 脂蛋白（a）新疗法：心血管风险评估和治疗的最新进展》。

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2024-04-01 Epub Date: 2024-02-05 DOI: 10.1007/s11883-024-01192-9

Anders Berg Wulff, Børge G Nordestgaard, Anne Langsted

{"title":"Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment.","authors":"Anders Berg Wulff, Børge G Nordestgaard, Anne Langsted","doi":"10.1007/s11883-024-01192-9","DOIUrl":"10.1007/s11883-024-01192-9","url":null,"abstract":"Purpose of review: Lipoprotein(a) is an important causal risk factor for cardiovascular disease but currently no available medication effectively reduces lipoprotein(a). This review discusses recent findings regarding lipoprotein(a) as a causal risk factor and therapeutic target in cardiovascular disease, it reviews current clinical recommendations, and summarizes new lipoprotein(a) lowering drugs.Recent findings: Epidemiological and genetic studies have established lipoprotein(a) as a causal risk factor for cardiovascular disease and mortality. Guidelines worldwide now recommend lipoprotein(a) to be measured once in a lifetime, to offer patients with high lipoprotein(a) lifestyle advise and initiate other cardiovascular medications. Clinical trials including antisense oligonucleotides, small interfering RNAs, and an oral lipoprotein(a) inhibitor have shown great effect on lowering lipoprotein(a) with reductions up to 106%, without any major adverse effects. Recent clinical phase 1 and 2 trials show encouraging results and ongoing phase 3 trials will hopefully result in the introduction of specific lipoprotein(a) lowering drugs to lower the risk of cardiovascular disease.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"111-118"},"PeriodicalIF":5.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139680771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions. 在 2023 年美国心脏协会科学会议上介绍的心血管疾病预防研究要点。

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2024-04-01 Epub Date: 2024-03-05 DOI: 10.1007/s11883-024-01193-8

Melody Hermel, Andrew Chiou, Abdul Mannan Khan Minhas, Maha Inam, Carly E Waldman, Eventine Youngblood, Sandeep Mehta, Leandro Slipczuk, Sana Sheikh, Chelsea Meloche, Adeel Khoja, Salim S Virani

{"title":"Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions.","authors":"Melody Hermel, Andrew Chiou, Abdul Mannan Khan Minhas, Maha Inam, Carly E Waldman, Eventine Youngblood, Sandeep Mehta, Leandro Slipczuk, Sana Sheikh, Chelsea Meloche, Adeel Khoja, Salim S Virani","doi":"10.1007/s11883-024-01193-8","DOIUrl":"10.1007/s11883-024-01193-8","url":null,"abstract":"Purpose of review: Focused review highlighting ten select studies presented at the 2023 American Heart Association (AHA) Scientific Sessions.Recent findings: Included studies assessed semaglutide and cardiovascular outcomes in overweight or obese patients without diabetes (SELECT); dapagliflozin in patients with acute myocardial infarction without diabetes (DAPA-MI); effects of dietary sodium on systolic blood pressure in middle-aged individuals (CARDIA-SSBP); long-term blood pressure control after hypertensive pregnancy with physician guided self-management (POP-HT); effect and safety of zilebesiran, an RNA interference therapy, for sustained blood pressure reduction (KARDIA-1); recaticimab add-on therapy in patients with non-familial hypercholesterolemia and mixed hyperlipidemia (REMAIN-2); efficacy and safety of lepodisiran an extended duration short-interfering RNA targeting lipoprotein(a); safety and pharmacodynamic effects of an investigational DNA base editing medicine that inactivates the PCSK9 gene and lowers LDL cholesterol (VERVE-101); automated referral to centralized pharmacy services for evidence-based statin initiation in high-risk patients; and effects of intensive blood pressure lowering in reducing risk of cardiovascular events (ESPRIT). Research presented at the 2023 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"119-131"},"PeriodicalIF":5.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140027613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implications of Bias in Artificial Intelligence: Considerations for Cardiovascular Imaging. 人工智能偏差的影响：心血管成像的考虑因素。

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2024-04-01 Epub Date: 2024-02-16 DOI: 10.1007/s11883-024-01190-x

Marly van Assen, Ashley Beecy, Gabrielle Gershon, Janice Newsome, Hari Trivedi, Judy Gichoya

{"title":"Implications of Bias in Artificial Intelligence: Considerations for Cardiovascular Imaging.","authors":"Marly van Assen, Ashley Beecy, Gabrielle Gershon, Janice Newsome, Hari Trivedi, Judy Gichoya","doi":"10.1007/s11883-024-01190-x","DOIUrl":"10.1007/s11883-024-01190-x","url":null,"abstract":"Purpose of review: Bias in artificial intelligence (AI) models can result in unintended consequences. In cardiovascular imaging, biased AI models used in clinical practice can negatively affect patient outcomes. Biased AI models result from decisions made when training and evaluating a model. This paper is a comprehensive guide for AI development teams to understand assumptions in datasets and chosen metrics for outcome/ground truth, and how this translates to real-world performance for cardiovascular disease (CVD).Recent findings: CVDs are the number one cause of mortality worldwide; however, the prevalence, burden, and outcomes of CVD vary across gender and race. Several biomarkers are also shown to vary among different populations and ethnic/racial groups. Inequalities in clinical trial inclusion, clinical presentation, diagnosis, and treatment are preserved in health data that is ultimately used to train AI algorithms, leading to potential biases in model performance. Despite the notion that AI models themselves are biased, AI can also help to mitigate bias (e.g., bias auditing tools). In this review paper, we describe in detail implicit and explicit biases in the care of cardiovascular disease that may be present in existing datasets but are not obvious to model developers. We review disparities in CVD outcomes across different genders and race groups, differences in treatment of historically marginalized groups, and disparities in clinical trials for various cardiovascular diseases and outcomes. Thereafter, we summarize some CVD AI literature that shows bias in CVD AI as well as approaches that AI is being used to mitigate CVD bias.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"91-102"},"PeriodicalIF":5.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy. 慢性肾脏病年轻患者的心血管风险增加与降脂疗法的作用。

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2024-04-01 Epub Date: 2024-01-30 DOI: 10.1007/s11883-024-01191-w

Vojtech Kratky, Anna Valerianova, Zdenka Hruskova, Vladimir Tesar, Jan Malik

{"title":"Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy.","authors":"Vojtech Kratky, Anna Valerianova, Zdenka Hruskova, Vladimir Tesar, Jan Malik","doi":"10.1007/s11883-024-01191-w","DOIUrl":"10.1007/s11883-024-01191-w","url":null,"abstract":"Purpose of review: Chronic kidney disease (CKD) is associated with a significantly increased risk of cardiovascular disease (CVD). This review summarizes known risk factors, pathophysiological mechanisms, and current therapeutic possibilities, focusing on lipid-lowering therapy in CKD.Recent findings: Novel data on lipid-lowering therapy in CKD mainly stem from clinical trials and clinical studies. In addition to traditional CVD risk factors, patients with CKD often present with non-traditional risk factors that include, e.g., anemia, proteinuria, or calcium-phosphate imbalance. Dyslipidemia remains an important contributing CVD risk factor in CKD, although the mechanisms involved differ from the general population. While statins are the most commonly used lipid-lowering therapy in CKD patients, some statins may require dose reduction. Importantly, statins showed diminished beneficial effect on cardiovascular events in patients with severe CKD and hypercholesterolemia despite high CVD risk and effective reduction of LDL cholesterol. Ezetimibe enables the reduction of the dose of statins and their putative toxicity and, in combination with statins, reduces CVD endpoints in CKD patients. The use of novel drugs such as PCSK9 inhibitors is safe in CKD, but their potential to reduce cardiovascular events in CKD needs to be elucidated in future studies.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"103-109"},"PeriodicalIF":5.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Psychological Health and Ischemic Heart Disease in Women: A Review of Current Evidence and Clinical Considerations across the Healthspan. 女性心理健康与缺血性心脏病：当前证据回顾与跨健康期的临床考虑。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-03-01 Epub Date: 2024-01-19 DOI: 10.1007/s11883-023-01185-0

Allison E Gaffey, Erica S Spatz

{"title":"Psychological Health and Ischemic Heart Disease in Women: A Review of Current Evidence and Clinical Considerations across the Healthspan.","authors":"Allison E Gaffey, Erica S Spatz","doi":"10.1007/s11883-023-01185-0","DOIUrl":"10.1007/s11883-023-01185-0","url":null,"abstract":"Purpose of review: Psychological health encompasses a constellation of negative and positive factors-i.e., psychosocial stress, depression, anxiety, trauma, loneliness and social isolation, anger and hostility, optimism, and a sense of purpose. This narrative review presents current evidence at the intersection of psychological health, risk of ischemic heart disease (IHD), and IHD-related outcomes, with an emphasis on associations in women.Recent findings: For women, relations between psychological health and IHD reflect important sex and gender differences in biological and psychosocial factors. Although efforts devoted to understanding psychological health and IHD risk have varied by psychological factor-scientific evidence is strongest for psychosocial stress and depression, while anxiety, trauma, and positive psychological factors warrant more investigation-less optimal psychological health is consistently associated with an earlier and greater risk of IHD morbidity and mortality in women. Still, many past prospective studies of psychological factors and IHD risk had a limited representation of women, did not include analyses by sex, or failed to account for other influential, sex-specific factors. Thus, there are multiple pathways for further, rigorous investigation into psychological health-IHD associations, mechanisms, and empirically supported psychological interventions to mitigate IHD risk among women. Given the robust evidence linking psychological health with women's risk for IHD, implementing routine, brief, psychological screening is recommended. Significant life events, developmental milestones specific to women, and IHD diagnoses or events could cue further psychological assessment and referral, efforts which will mutually strengthen the evidence for integrated psychological and IHD care and delivery of such care to this vulnerable group.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"45-58"},"PeriodicalIF":5.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11219074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139491167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon? 我们是否需要预防动脉粥样硬化的疫苗？我们能否很快得到疫苗？

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-03-01 Epub Date: 2024-01-02 DOI: 10.1007/s11883-023-01186-z

Stanisław Surma, Amirhossein Sahebkar, Maciej Banach

{"title":"Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?","authors":"Stanisław Surma, Amirhossein Sahebkar, Maciej Banach","doi":"10.1007/s11883-023-01186-z","DOIUrl":"10.1007/s11883-023-01186-z","url":null,"abstract":"Purpose of review: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of premature death. Lipid disorders, particularly elevated serum low-density lipoprotein cholesterol (LDL-C), contribute significantly to ASCVD. The risk of developing ASCVD is influenced by the duration of exposure to elevated LDL-C concentrations (cholesterol-years concept). Implementing lipid-lowering treatments based on the principles of \"the earlier the better,\" \"the lower the better,\" and \"the longer the better\" has been shown to reduce cardiovascular risk and significantly extend lifespan. Despite the availability of numerous lipid-lowering drugs, achieving satisfactory control of lipid disorders remains very challenging. Therefore, there is a need for novel approaches to improve treatment adherence.Recent findings: One promising solution under investigation is the development of an anti-PCSK9 vaccine, which could be administered annually to provide long-term control over LDL-C concentrations. Experimental studies and the sole clinical trial conducted thus far have demonstrated that the anti-PCSK9 vaccine induces a durable immune response associated with lipid-lowering and anti-atherosclerotic effects. Furthermore, it has exhibited good tolerability and a satisfactory safety profile. However, we still need data from phase 2, 3, and cardiovascular outcome trial to confirm its safety and efficacy and add value in the armamentarium of available and perspective lipid-lowering drugs. This article highlights the significance of developing an anti-PCSK9 vaccine and provides an overview of the current knowledge on various anti-PCSK9 vaccines.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"59-71"},"PeriodicalIF":5.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10881686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139073610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipoprotein(a): from Causality to Treatment. 脂蛋白（a）：从成因到治疗。

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2024-03-01 Epub Date: 2024-01-22 DOI: 10.1007/s11883-024-01187-6

Florian Kronenberg

{"title":"Lipoprotein(a): from Causality to Treatment.","authors":"Florian Kronenberg","doi":"10.1007/s11883-024-01187-6","DOIUrl":"10.1007/s11883-024-01187-6","url":null,"abstract":"Purpose of review: This paper reviews the evidence why lipoprotein(a) (Lp(a)) is a causal risk factor for cardiovascular disease and how high Lp(a) concentrations should be managed now and with an outlook to the future.Review findings: No optimal and widely available animal models exist to study the causality of the association between Lp(a) and cardiovascular disease. This has been a major handicap for the entire field. However, genetic studies turned the page. Already in the early 1990s, the principle of Mendelian randomization studies was applied for the first time ever (even if they were not named so at that time). Genetic variants of the LPA gene such as the apolipoprotein(a) isoform size, the number and sum of kringle IV repeats and later single nucleotide polymorphisms are strongly associated with life-long exposure to high Lp(a) concentrations as well as cardiovascular outcomes. This evidence provided a basis for the development of specific Lp(a)-lowering drugs that are currently in clinical testing phase. Lp(a) is one of the most important genetically determined risk factors for cardiovascular disease. With the specific Lp(a)-lowering therapies, we might get tools to fight this common risk factor in case the outcome trials will be positive.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"75-82"},"PeriodicalIF":5.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10881767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139511520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How Will Our Practice Change After the CLEAR Outcomes Trial? CLEAR 成果试验后，我们的实践会有什么变化？

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2024-03-01 Epub Date: 2024-01-31 DOI: 10.1007/s11883-024-01188-5

Timothy Abrahams, Adam J Nelson, Stephen J Nicholls

{"title":"How Will Our Practice Change After the CLEAR Outcomes Trial?","authors":"Timothy Abrahams, Adam J Nelson, Stephen J Nicholls","doi":"10.1007/s11883-024-01188-5","DOIUrl":"10.1007/s11883-024-01188-5","url":null,"abstract":"Purpose of review: Bempedoic acid is a novel therapeutic agent that is designed to reduce levels of low-density lipoprotein cholesterol (LDL-C). The purpose of this review is to provide the background for development of bempedoic acid, findings from clinical trials and to discuss clinical implications.Recent findings: Bempedoic acid inhibits ATP citrate lyase within the liver and reduces cholesterol synthesis, with the potential to avoid muscle symptoms experienced by patients treated with statins. Early clinical studies demonstrated that administration of bempedoic acid resulted in lowering of LDL-C by 20-30% as monotherapy and by 40-50% when combined with ezetimibe, in addition to lowering of high sensitivity C-reactive protein by 20-30%. The CLEAR Outcomes trial of high cardiovascular risk patients, with elevated LDL-C levels and either unable or unwilling to take statins demonstrated that bempedoic acid reduced the rate of major adverse cardiovascular events. A greater incidence of elevation of hepatic transaminase and creatinine, gout, and cholelithiasis were consistently observed in bempedoic acid-treated patients. Bempedoic acid presents an additional therapeutic option to achieve more effective lowering of LDL-C levels and reduction in cardiovascular risk.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"83-89"},"PeriodicalIF":5.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10881600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting the Gut Microbiome to Treat Cardiometabolic Disease. 针对肠道微生物组治疗心脏代谢疾病。

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2024-02-01 Epub Date: 2024-01-05 DOI: 10.1007/s11883-023-01183-2

Panagiotis Theofilis, Panayotis K Vlachakis, Evangelos Oikonomou, Konstantinos Tsioufis, Dimitris Tousoulis

{"title":"Targeting the Gut Microbiome to Treat Cardiometabolic Disease.","authors":"Panagiotis Theofilis, Panayotis K Vlachakis, Evangelos Oikonomou, Konstantinos Tsioufis, Dimitris Tousoulis","doi":"10.1007/s11883-023-01183-2","DOIUrl":"10.1007/s11883-023-01183-2","url":null,"abstract":"Purpose of review: Cardiometabolic diseases, which include obesity, type 2 diabetes, and cardiovascular diseases, constitute a worldwide health crisis of unparalleled proportions. The human gut microbiota has emerged as a prominent topic of inquiry in the search for novel treatment techniques. This review summarizes current research on the potential of addressing the gut microbiota to treat cardiometabolic disease.Recent findings: Recent studies have highlighted a complex link between the gut microbiota and host physiology, shedding light on the several processes through which gut microorganisms impact metabolic health, inflammation, and cardiovascular function. Furthermore, a growing corpus of research is available on microbiome-based therapies such as dietary interventions, probiotics, prebiotics, synbiotics, and fecal microbiota transplantation. These therapies show promise as methods for reshaping the gut microbiota and, as a result, improving cardiometabolic outcomes. However, hurdles remain, ranging from the intricacies of microbiome research to the necessity for tailored treatments that take individual microbial variations into consideration, emphasizing the significance of furthering research to bridge the gap between microbiome science and clinical practice. The gut microbiome is a beacon of hope for improving the management of cardiometabolic disease in the age of precision medicine, since its association with their pathophysiology is constantly being unraveled and strengthened. Available studies point to the potential of gut microbiome-based therapeutics, which remains to be tested in appropriately designed clinical trials. Further preclinical research is, however, essential to provide answers to the existing obstacles, with the ultimate goal of enhancing patient care.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"25-34"},"PeriodicalIF":5.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0